Seattle Genetics Highlights SGN-70 at AAI Annual Meeting

   "We believe that autoimmune disease represents a significant opportunity for SGN-70 due to the expression of CD70 on activated, but not on resting T- and B-cells," said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "Our AAI presentations demonstrate compelling data in preclinical models of autoimmune disease, and support our plan to initiate clinical trials of SGN-70 during 2008."

   Data presented today in a poster presentation entitled "Immune Modulation Mediated by the Humanized Anti-CD70 Monoclonal Antibody SGN-70" describe the expression of CD70 on activated T- and B-cells and in autoimmune disease tissues, and demonstrate that SGN-70 inhibits T- and B-cell functions and selectively depletes CD70-positive activated T-cells (Abstract #LB457).

   In addition, Dr. Iqbal Grewal, Vice President, Preclinical Therapeutics at Seattle Genetics, presented on Monday at an AAI Major Symposium on the company's anti-CD70 therapies, SGN-70 and SGN-75, for the treatment of autoimmune diseases and cancer. SGN-75 is an antibody-drug conjugate (ADC) that has demonstrated potent antitumor activity at well-tolerated doses in preclinical models of renal cell cancer and CD70-positive hematologic malignancies. Seattle Genetics is advancing SGN-75 towards clinical trials in solid tumors and hematologic malignancies.

   Seattle Genetics' SGN-70 poster is available from the "Technology" section of the company's website at www.seattlegenetics.com.

   Keywords: Autoimmune Diseases, Autoimmune Disorder, Autoimmunity, Biotechnology, Cancer, Clinical Trial Research, Clinical Trials, Genetics, Immunology, Inflammation, Medical Device, Monoclonal Antibody, Oncology, Pre-Trials Research, Therapy, Treatment, Seattle Genetics Inc.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.

Return to Genetics Business Alert Section